Dixon Hubard Feinour & Brown Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$8.17M |
| 2 |
NVIDIA
NVDA
|
+$7.7M |
| 3 |
Trimble
TRMB
|
+$7.43M |
| 4 |
Vanguard Short-Term Bond ETF
BSV
|
+$6.37M |
| 5 |
iShares MBS ETF
MBB
|
+$6.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
lululemon athletica
LULU
|
+$9.18M |
| 2 |
Veeva Systems
VEEV
|
+$8.32M |
| 3 |
Netflix
NFLX
|
+$7.43M |
| 4 |
PPG Industries
PPG
|
+$1.7M |
| 5 |
BNY
Bank of New York Mellon
BNY
|
+$1.29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.74% |
| 2 | Healthcare | 19.11% |
| 3 | Miscellaneous | 15.3% |
| 4 | Consumer Discretionary | 9.45% |
| 5 | Financials | 7.79% |
Similar funds
Dixon Hubard Feinour & Brown's Q2 2021 Portfolio in Review
As of Q2 2021, Dixon Hubard Feinour & Brown held 201 positions worth $481M, up 14% from $422M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Dixon Hubard Feinour & Brown deployed $24.8M of net new capital in Q2 2021, opening 24 new positions and adding to 52 existing holdings. Its largest new stake was CVS Health: 99,762 shares worth $8.32M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Healthcare and Miscellaneous.
On the sell side, the largest reduction was lululemon athletica, an estimated $9.18M trimmed.
- Dixon Hubard Feinour & Brown's largest Q2 2021 buy was CVS Health: 99,762 shares worth $8.32M.
- Dixon Hubard Feinour & Brown added most to NVIDIA in Q2 2021, an estimated $7.7M increase.
- Dixon Hubard Feinour & Brown's biggest Q2 2021 reduction was lululemon athletica, cutting an estimated $9.18M.
- Dixon Hubard Feinour & Brown fully exited Netflix in Q2 2021, selling an estimated $7.43M.
- Dixon Hubard Feinour & Brown's ten largest holdings make up 34% of its $481M portfolio in Q2 2021.
- Dixon Hubard Feinour & Brown opened 24 new positions and closed 16 in Q2 2021.
- Dixon Hubard Feinour & Brown's portfolio value rose 14% quarter-over-quarter to $481M.
Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2021, filed 23 Aug 2021.